18 Jul Broken String Biosciences
Felix Dobbs, Ph.D., CEO
Oct. 7 | 5:45pm | FLW Ballroom F
Cambridge, England
(Private)
Broken String Biosciences is advancing the safety and precision of cell and gene therapies through its proprietary INDUCE-seq® platform. INDUCE-seq® has become the leading choice for unbiased, PCR-free detection of genome-wide DNA double-strand breaks, enabling drug developers to simultaneously identify both on- and off-target edits with high resolution in days, not months. Offered as both a full-service solution and an in-lab kit, INDUCE-seq® supports therapeutic development from discovery through commercialization. It is validated for use in optimizing editing efficiency in iPSC- and T cell–based therapies, and for evaluating emerging technologies like base editors, and improving guide RNA design. INDUCE-seq®is quickly becoming an established standard in safety assessments through participation in the NIST Genome Editing Consortium with HESI, which is establishing industry standards for safe gene editing.
